Low Testosterone May Predict Worse Prostate Cancer Outcomes

Share this content:
Preoperative levels below 300 ng/dL are associated with an increased risk.
Preoperative levels below 300 ng/dL are associated with an increased risk.

Low testosterone levels prior to radical prostatectomy (RP) for prostate cancer (PCa) are associated with worse oncologic outcomes, new findings suggest.

In a study of 177 men who had their preoperative testosterone levels measured and underwent RP, a team led by R. Jeffrey Karnes, MD, of Mayo Clinic in Rochester, Minn., found that patients with a low preoperative testosterone level (below 300 ng/dL) had a significantly higher risk of positive surgical margins and seminal vesicle invasion compared with men who had normal testosterone levels before surgery

Low testosterone was associated with a slightly, but not significantly, higher rate of biochemical failure, the investigators reported in the Journal of Men's Health (2014;10:129-133).

Patients had a median preoperative testosterone level of 423 ng/dL  and a median age of 65 years. Of the 177 patients, 40 had low and 137 had normal testosterone. The study had a median follow-up of about 15 years, making it the longest follow-up to date correlating preoperative testosterone levels with biochemical failure in men undergoing RP, the researchers noted.

Positive surgical margins and seminal vesicle invasion were found in 47.5% and 22.5%, respectively, of the low testosterone group compared with 29.9% and 8%, respectively, of the normal testosterone group.

“The data add to the accumulating evidence that low testosterone levels could potentially be an adverse factor in prostate cancer patients,” Dr. Karnes' group concluded.

You must be a registered member of Renal and Urology News to post a comment.

Sign up for free e-Newsletters